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In an effort to improve follow-up data collection and to foster patient involvement, the LCBRN created a newsletter that was mailed out to currently enrolled patients in February of 2014 (See Figure 1) . The newsletter provided information on the purpose of the LCBRN, the types of projects being supported, and emphasized the importance of patient participation in furthering lung cancer research. Patients were asked to call their LCBRN Coordinators to update them on their progress post-surgery. 
Informatics
The LCBRN's central database stores subject identification, clinical data and tracks all aspects of biospecimen procurement. The patient, specimen, QC, search, and specimen inventory modules of the database are fully operational and are being used at the Coordinating Center and all Biospecimen Resource Sites. During this last year, the Informatics team finished building the search functions of the LCBRN database which allows the Coordinating Center to target samples for distribution. Figure 2 is a screen shot of the Specimen Search module. This latest version is able to filter out hemolyzed plasma and serum samples as well as fluid samples that were processed 4 hours after collection. The informatics team also finalized a module to track investigator and specimen distribution information. This distribution module allows the Coordinating Center to easily assign large number of specimens to one investigator for distribution. Once the samples are assigned, Subject and Specimen Detail Reports are generated through JasperServer Reports and accompany all samples shipped to investigators. Figure 3 is a snapshot of the distribution module. The LCBRN website (http://www.lcbrn.org) has been updated monthly to reflect the current subject enrollment numbers, the percentage of tumors collected, and the percentage of enrolled patients currently in follow-up. In addition, digital H&E images of the FFPE tumors have been updated as they become available. Scanned images can be found on the Access H&E Images page of the LCBRN website.
Standard Operating Procedures (SOPs)
SOPs dealing with biorepository activities are available at the LCBRN Collab online resource (https://collab.itc.virginia.edu/portal) and on the LCBRN public website. There have been no significant updates to any of the SOPs during this reporting period. The LCBRN conference calls take place on a monthly basis. Topics for conference calls have dealt with subject enrollment, follow-up specimen and data collection, and informatics. Calls and meetings have occurred on the following dates: 
Biospecimen Collection and Quality Control
Histologic and molecular quality control have been performed at regular intervals on tissue from all 3 Resource Sites. RQI values of 7 or above indicate excellent quality RNA, values between 4 and 7 are considered moderate, and any values below 4 indicate poor quality RNA. The majority of tissue samples from all LCBRN Resource Sites fall into the moderate to excellent quality range (average RQI of 6.1).
The LCBRN distributed 10 RNA samples to an LCBRN approved investigator for a pilot study that would test the presence of tumor cells in the plasma buffy coat samples collected by the LCBRN. Real-time RT-PCR was performed on the buffy coat and was then repeated for direct comparison to whole blood RNA.
The results showed that all the signals in the buffy coat prep were substantially lower than in the reference set. Additionally, the LCBRN Coordinating Center performed RNA extraction on 86 buffy coat samples and found the RNA to generally be degraded beyond acceptable quality measures (average RQI of 3.6). The reasons for the loss of RNA stability from the cells in these preparations is unclear, however given these results, the LCBRN will no longer extract RNA from buffy coat samples. DNA, instead, will be the primary derivative offered from the buffy coat prep.
The LCBRN received feedback from an investigator regarding his inability to use serum or blood samples with hemolysis. It is not uncommon for blood draws to be hemolyzed and for clinical labs to refuse these samples since the hemolyzed red blood cells can interfere with some assays. Because hemolysis can be caused by many factors including difficult blood draws, unsecure line connections, incorrect needle size or handling blood tubes too vigorously, one cannot predict which cases will be affected. Additionally, hemolyzed samples are only able to be recognized after the samples are processed by the biorepository; they are identified by the pink hue of the fluid. Since the LCBRN did not foresee some investigators not being able to use these types of samples, hemolyzed samples were not tracked in the database. In order to address this issue, a line item asking if investigators would be willing to accept hemolyzed plasma or serum samples was added to the LCBRN investigator application and functionality was built into the database to track hemolyzed serum and plasma samples both retrospectively and prospectively.
Data Quality Assessment
A data audit sampling the source forms of 15 randomly selected patients from each Resource Site. The purpose of the audit was make certain required clinical data was being collected and captured accurately in the database and that follow-up data was being collected at the specified timelines. Each Resource Sites was also issued a null value report that listed any subjects who have clinical data fields that were missing values in the central database. All Sites were provided feedback regarding any discrepancies in data entry and corrections to the database were made. There were no other significant findings as a result of this audit.
Distribution
The Coordinating Center received a total of 94 inquires from investigators seeking information about the LCBRN's resources since the start of distribution. 24 investigators have submitted applications; 15 were accepted without any changes, 6 were accepted with modifications, 2 are pending IRB approval, and 1 was rejected. The investigators with applications that were accepted with modifications were given suggestions to make better use of LCBRN resources, or had research that was deemed too risky and were therefore offered a smaller sample set than was originally requested for the purpose of obtaining preliminary results. The application that was rejected was due to the rare type of tumor requested. A summary of the 1802 biospecimens that have been shipped are outlined in Table 2 below. The LCBRN submitted an application to the NCI for their Assay Development Program in September 2013 in response to their request seeking applications from tissue and laboratory resources. The application proposed that the NCI subcontract the LCBRN for any of their lung cancer biospecimen needs, which will in turn help the LCBRN increase sample distribution while providing researchers with a valuable resource. The NCI recently approved the LCBRN's application and distribution will begin in the coming months. 
Section V: Conclusion
The LCBRN has met the majority of the organizational metrics laid out in the Statement of Work for Year 4. Whereas the consortium was expected to enroll 600 subjects from the start of the grant, it has instead enrolled 764, easily surpassing its goal of 150 subjects enrolled per year. In addition, the majority of tissue specimens collected thus far by the LCBRN have passed both histology and molecular quality control metrics, with feedback mechanisms in place to achieve improvements where needed. The LCBRN is also successfully reviewing applications for suitability and distributing samples to investigators, all of whom have given positive feedback. Concerns regarding the underutilization of LCBRN resources were addressed with rigorous marketing efforts to increase its visibility in the research community. This campaign was undertaken in August 2013 and helped to improve awareness as depicted by the increased number of inquires received by the Coordinating Center. The Coordinating Center will send out another marketing email in November 2014 to the Directors of all NCI-designated Cancer Centers and to 187 researchers who have applied to the NIH for a lung cancer grant and thus are likely to utilize LCBRN resources. In addition, the forthcoming collaboration with the NCI for their Assay Development Program will also help to increase LCBRN sample usage.
Although new subject enrollments and specimen collection have ceased, the LCBRN is committed to the outcome of this project, which is a bank of high quality and highly annotated biospecimens from lung cancer patients that will support research into the molecular basis of this disease, the discovery of diagnostic and prognostic biomarkers, and the validation of new biomarker assays. Samples will continue to be distributed under the support of the Department of Defense CDMRP until a plan to absorb any remaining biospecimens into the Cooperative Human Tissue Network (CHTN), for which the LCBRN Coordinating Center P.I. is a member, is complete. It is a priority that this valuable resource remains available to the general research community, with a panel of experts ensuring its judicious use by projects with a significant likelihood of creating new knowledge of human lung cancer and innovative tools for the diagnosis and treatment of this disease. 
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